Post-ERCP Pancreatitis
14
2
2
5
Key Insights
Highlights
Success Rate
71% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
14.3%
2 terminated out of 14 trials
71.4%
-15.1% vs benchmark
43%
6 trials in Phase 3/4
60%
3 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (14)
Spontaneous Dislocation and Adverse Events of a Prophylactic Pancreatic Stent
Dose-escalation of Rectal Indomethacin for Preventing PEP
Low-Dose vs Standard-Dose Indomethacin for Preventing Post-ERCP Pancreatitis
Frequency and Predictors of Post-ERCP Pancreatitis in a South Asian Tertiary Care Center
Early Pancreatic Stent Placement for Preventing PEP
Stent vs. Indomethacin for Preventing Post-ERCP Pancreatitis
Effects of High FIO2 on Post-ERCP Pancreatitis.
Refeeding in Post-ERCP Pancreatitis
The Efficacy of Pancreatic Duct Stenting With Rectal Indomethacin in Preventing Post-ERCP Pancreatitis
Magnesium Sulfate in the Prevention of Post-ERCP Pancreatitis.
Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis
Pharmacological Prophylaxis of Post- Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis
Rectal Indomethacin in the Prevention of Post-endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis in High Risk Patients
Comparison Of Loop-Tip Wire Vs Tradictional Technique In The Cannulation Of The Common Bile Duct